What is the level of liabilities of CardieX this year?
CardieX has a debt balance of 8.32 M AUD this year.
CardieX Liabilities 2024
CardieX Liabilities
8.32 M AUD
Ticker
CDX.AX
ISIN
AU0000015729
WKN
A2JN9Z
In 2024, CardieX's total liabilities amounted to 8.32 M AUD, a 44.21% difference from the 5.77 M AUD total liabilities in the previous year.
CardieX Aktienanalyse
What does CardieX do?
Cardiex Ltd is an Australian medical technology company specializing in the development and marketing of cardiovascular monitoring systems and diagnostic tools. The company was founded in 1996 and is based in Melbourne. Cardiex's history begins with the development of SphygmoCor technology in collaboration with researchers from Monash University. This technology allows for non-invasive measurement of pulse and blood pressure waves in the arteries, providing information about the condition of the cardiovascular system. Cardiex's first product was the SphygmoCor Analyzer, which was launched in 1999. Over time, additional products and technologies have been developed to meet the growing demand for cardiovascular monitoring and diagnostics. Cardiex's business model is based on the development and marketing of innovative medical technologies for the international market. The company works closely with clinics, research institutions, and medical device manufacturers to develop products that meet the needs of the healthcare sector. Cardiex has a comprehensive network of sales and marketing partners in over 40 countries worldwide. Cardiex operates in several divisions, including: - Diagnostic Systems: This division includes products such as the SphygmoCor Analyzer, which assesses arterial health, and the Arterial Stiffness Scanner, which enables early detection of cardiovascular risk factors. - Telemedicine: Cardiex offers a telehealth platform that allows clinics and medical personnel to monitor and analyze patient data in real-time. The platform can be used for remote patient monitoring, early detection of complications, and treatment optimization. - Research and Development: Cardiex collaborates closely with researchers and medical institutions to develop new technologies for cardiovascular monitoring and diagnostics. The company invests heavily in research and development to maintain a leading role in the field of medical technology. An important aspect of Cardiex's business model is its partnership with other companies. The company works closely with device manufacturers, software developers, and other service providers to integrate its technologies and products, offering complete solutions for the healthcare sector. Cardiex's products include not only the SphygmoCor Analyzer but also the Arterial Stiffness Scanner, Ambulatory Blood Pressure Monitor, CardiexCare data management system, and telehealth platform. All these products are designed to simplify and improve the monitoring and diagnosis of cardiovascular diseases. Overall, Cardiex is a successful medical technology company specializing in the development and marketing of innovative cardiovascular monitoring systems and diagnostic tools. The company has expanded its product and service offerings in recent years and has a strong international presence. Through close collaboration with other companies and research institutions, Cardiex will continue to play a leading role in the field of medical technology in the future. CardieX ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing CardieX's Liabilities
CardieX's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating CardieX's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing CardieX's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
CardieX's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in CardieX’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about CardieX stock
What were the liabilities of CardieX compared to the previous year?
The liabilities of CardieX have increased by 44.21% increased compared to the previous year.
What are the consequences of high debt for investors of CardieX?
High liabilities can pose a risk for investors of CardieX, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in CardieX?
Low liabilities mean that CardieX has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of CardieX affect the company?
An increase in liabilities of CardieX can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of CardieX affect the company?
A decrease in the liabilities of CardieX can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of CardieX?
Some factors that can influence the liabilities of CardieX include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of CardieX so important for investors?
The liabilities of CardieX are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can CardieX take to modify the liabilities?
To change its liabilities, CardieX can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does CardieX pay?
Over the past 12 months, CardieX paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, CardieX is expected to pay a dividend of 0 AUD.
What is the dividend yield of CardieX?
The current dividend yield of CardieX is .
When does CardieX pay dividends?
CardieX pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of CardieX?
CardieX paid dividends every year for the past 0 years.
What is the dividend of CardieX?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is CardieX located?
CardieX is assigned to the 'Health' sector.
Wann musste ich die Aktien von CardieX kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of CardieX from 11/8/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 11/8/2024.
When did CardieX pay the last dividend?
The last dividend was paid out on 11/8/2024.
What was the dividend of CardieX in the year 2023?
In the year 2023, CardieX distributed 0 AUD as dividends.
In which currency does CardieX pay out the dividend?
The dividends of CardieX are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von CardieX
Our stock analysis for CardieX Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CardieX Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
